R

Rocket Pharmaceuticals
D

RCKT

2.93500
USD
-0.13
(-4.09%)
مغلق
حجم التداول
96,394
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
316,210,792
أصول ذات صلة
AAPL
AAPL
-2.730
(-1.37%)
196.455 USD
AMZN
AMZN
-1.090
(-0.51%)
212.140 USD
BA
BA
-3.320
(-1.63%)
200.420 USD
GOOG
GOOG
-1.090
(-0.62%)
175.900 USD
LMT
LMT
17.05
(3.63%)
486.26 USD
MSFT
MSFT
-4.07
(-0.85%)
474.96 USD
NOC
NOC
19.91
(4.01%)
517.00 USD
S
SPCE
-0.02000
(-0.66%)
3.00000 USD
TSLA
TSLA
6.17
(1.93%)
325.36 USD
المزيد
الأخبار المقالات

العنوان: Rocket Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.